MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 28 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $11,929,000 | +58.9% | 4,696,464 | +27.0% | 0.00% | – |
| Q1 2020 | $7,508,000 | -0.8% | 3,698,598 | +5.6% | 0.00% | – |
| Q4 2019 | $7,565,000 | +115.2% | 3,502,269 | +53.5% | 0.00% | – |
| Q3 2019 | $3,515,000 | -67.3% | 2,282,282 | -11.8% | 0.00% | – |
| Q2 2019 | $10,737,000 | +3.9% | 2,587,314 | +4.7% | 0.00% | – |
| Q1 2019 | $10,333,000 | +62.9% | 2,472,020 | +11.9% | 0.00% | – |
| Q4 2018 | $6,343,000 | -59.3% | 2,209,902 | +41.7% | 0.00% | -100.0% |
| Q3 2018 | $15,595,000 | +40.2% | 1,559,493 | -0.9% | 0.00% | – |
| Q2 2018 | $11,123,000 | +123.8% | 1,573,281 | +20.9% | 0.00% | – |
| Q1 2018 | $4,971,000 | -52.1% | 1,301,219 | +2.4% | 0.00% | – |
| Q4 2017 | $10,374,000 | +111.6% | 1,271,322 | +52.2% | 0.00% | – |
| Q3 2017 | $4,903,000 | +512.9% | 835,263 | +43.1% | 0.00% | – |
| Q2 2017 | $800,000 | -30.9% | 583,654 | -10.7% | 0.00% | – |
| Q1 2017 | $1,157,000 | +515.4% | 653,651 | +249.9% | 0.00% | – |
| Q4 2016 | $188,000 | -71.7% | 186,821 | -48.9% | 0.00% | – |
| Q3 2016 | $665,000 | +84.7% | 365,699 | +29.0% | 0.00% | – |
| Q2 2016 | $360,000 | -75.7% | 283,380 | +2.8% | 0.00% | – |
| Q1 2016 | $1,484,000 | +5.4% | 275,762 | +49.6% | 0.00% | – |
| Q4 2015 | $1,408,000 | +204.1% | 184,321 | +232.0% | 0.00% | – |
| Q3 2015 | $463,000 | +22.2% | 55,520 | +69.8% | 0.00% | – |
| Q2 2015 | $379,000 | – | 32,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 1,192,883 | $15,329,000 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 1,431,059 | $18,389,000 | 1.71% |
| Avoro Capital Advisors LLC | 3,000,000 | $38,550,000 | 0.55% |
| Palo Alto Investors LP | 31,330 | $403,000 | 0.02% |